Warning Letter Record: Extra Medication / www.extramedication.com (2026-06-23) — Unapproved New Drugs/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Misbranded
TL;DR
The short version: The FDA issued a warning letter to Extra Medication (www.extramedication.com, FEI 3043544171) on June 23, 2026, citing violations of the Federal Food, Drug, and Cosmetic Act for introducing unapproved and misbranded ketamine products into interstate commerce, including products marketed as "Calypsol" and "Ketanest" (MARCS-CMS 725152). The FDA identified that these products lack required Section 505 approval, lack appropriate labeling, and pose safety risks due to lack of medical supervision and potential contamination or counterfeit ingredients. The FDA requests that Extra Medication cease offering these unapproved and misbranded drugs and warns that failure to address violations may result in seizure and injunction.
Argus analysis
# FDA Warning Letter Analysis: Extra Medication
**Company and Violations**
Extra Medication, operating at www.extramedication.com (FEI 3043544171), received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on June 23, 2026, for introducing unapproved and misbranded ketamine products into interstate commerce. The FDA conducted a website review on March 2, 2026, and documented the sale of ketamine products marketed as "Calypsol" and "Ketanest" without FDA approval. The agency identified significant public health risks, particularly given ketamine's potency and the absence of medical supervision in online sales environments. The letter emphasizes that unapproved drugs lack FDA's safety and effectiveness assurances and may be contaminated, counterfeit, or contain inconsistent active ingredients.
**Regulatory Citations and Meaning**
The violations cited sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act. Section 505(a) prohibits introducing new drugs into interstate commerce without FDA approval. Section 502(f)(1) requires adequate directions for safe lay use; prescription drugs cannot meet this standard since they require professional oversight. Section 503(b)(1) restricts prescription drugs to licensed practitioner supervision only. These citations establish that Extra Medication violated foundational drug approval and labeling requirements. The letter also notes that FDA-approved ketamine products (KETALAR) and esketamine (SPRAVATO) carry significant regulatory safeguards, including controlled substance scheduling and risk evaluation programs absent from the company's offerings.
**Response Timeline and Monitoring**
The warning letter requests immediate cessation of unapproved drug sales, with no specific compliance deadline stated. Peer compliance officers should monitor for FDA enforcement actions—seizure, injunction, or criminal referral—which typically follow unaddressed warning letters within 30 to 90 days. Watch for any public FDA announcements regarding enforcement, updated warning letter responses, or consent decrees. The case demonstrates FDA's active enforcement posture on internet pharmaceutical sales, particularly for controlled substances and high-risk injectable products.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Extra Medication / www.extramedication.com MARCS-CMS 725152 — June 23, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: Extra Medication / www.extramedication.com United States support@extramedication.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States June 23, 2026 WARNING LETTER Reference Number: MARCS-CMS 725152 To Extra Medication: This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.extramedication.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. As discussed below, FDA has observed that www.extramedication.com introduces into interstate commerce unapproved and misbranded ketamine drug products, including certain drugs for which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS). 1 FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved and misbranded ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. There are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Accordingly, FDA requests that www.extramedication.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm. FDA Review Violations were identified and documented during a review of your website www.extramedication.com, FDA Establishment Identifier (FEI) 3043544171, on March 2, 2026. Violations of the Federal Food, Drug, and C…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Is the FDA warning letter to Extra Medication / www.extramedication.com publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/extra-medication-wwwextramedicationcom-725152-06232026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Warning Letter Record: Extra Medication / www.extramedication.com (2026-06-23) — Unapproved New Drugs/Misbranded. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-extra-medication-www-extramedication-com-2026-06-23-unapproved-drug
"Warning Letter Record: Extra Medication / www.extramedication.com (2026-06-23) — Unapproved New Drugs/Misbranded." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-extra-medication-www-extramedication-com-2026-06-23-unapproved-drug.
Argus HQ Research. "Warning Letter Record: Extra Medication / www.extramedication.com (2026-06-23) — Unapproved New Drugs/Misbranded." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-extra-medication-www-extramedication-com-2026-06-23-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_extra_medication_www_extramedication_com_2026_06_23_unapproved_drug_2026,
title = {Warning Letter Record: Extra Medication / www.extramedication.com (2026-06-23) — Unapproved New Drugs/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-extra-medication-www-extramedication-com-2026-06-23-unapproved-drug},
note = {Accessed: July 13, 2026}
}